Literature DB >> 10332503

Heparin in inflammation: potential therapeutic applications beyond anticoagulation.

D J Tyrrell1, A P Horne, K R Holme, J M Preuss, C P Page.   

Abstract

In this chapter we have described anti-inflammatory functions of heparin distinct from its traditional anticoagulant activity. We have presented in vivo data showing heparin's beneficial effects in various preclinical models of inflammatory disease as well as discussed some clinical studies showing that the anti-inflammatory activities of heparin may translate into therapeutic uses. In vivo models that use low-anticoagulant heparins indicate that the anticoagulant activity can be distinguished from heparin's anti-inflammatory properties. In certain cases such as hypovolemic shock, the efficacy of a low-anticoagulant heparin derivative (GM1892) exceeds heparin. Data also suggest that nonconventional delivery of heparin, specifically via inhalation, has therapeutic potential in improving drug pharmacokinetics (as determined by measuring blood coagulation parameters) and in reducing the persistent concerns of systemic hemorrhagic complications. Results from larger clinical trials with heparin and LMW heparins are eagerly anticipated and will allow us to assess our predictions on the effectiveness of this drug class to treat a variety of human inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10332503     DOI: 10.1016/s1054-3589(08)60471-8

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  51 in total

1.  The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin.

Authors:  Helen Jones; William Paul; Clive P Page
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  Heparan sulfate-protein binding specificity.

Authors:  M A Nugent; J Zaia; J L Spencer
Journal:  Biochemistry (Mosc)       Date:  2013-07       Impact factor: 2.487

3.  Regulation of PMA-induced MUC5AC expression by heparin in human bronchial epithelial cells.

Authors:  Qi Li; Rui Xia Lei; Xiang Dong Zhou; Victor P Kolosov; Juliy M Perelman
Journal:  Mol Cell Biochem       Date:  2011-10-05       Impact factor: 3.396

4.  Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.

Authors:  L Borsig; R Wong; J Feramisco; D R Nadeau; N M Varki; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 5.  Heparan sulfate signaling in cancer.

Authors:  Erik H Knelson; Jasmine C Nee; Gerard C Blobe
Journal:  Trends Biochem Sci       Date:  2014-04-19       Impact factor: 13.807

Review 6.  The Role of Heparan Sulfate in Inflammation, and the Development of Biomimetics as Anti-Inflammatory Strategies.

Authors:  Brooke L Farrugia; Megan S Lord; James Melrose; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

7.  The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells.

Authors:  A Smailbegovic; R Lever; C P Page
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

8.  Inhibition of osteolytic bone metastasis by unfractionated heparin.

Authors:  Colin K Yee; Martin Butcher; Melec Zeadin; Jeffrey I Weitz; Stephen G Shaughnessy
Journal:  Clin Exp Metastasis       Date:  2008-09-24       Impact factor: 5.150

9.  Antithrombotic therapy in cardiac embolism.

Authors:  Alvaro Cervera; Angel Chamorro
Journal:  Curr Cardiol Rev       Date:  2010-08

10.  Lipoprotein Lipase Deficiency Impairs Bone Marrow Myelopoiesis and Reduces Circulating Monocyte Levels.

Authors:  Chuchun L Chang; Itsaso Garcia-Arcos; Rakel Nyrén; Gunilla Olivecrona; Ji Young Kim; Yunying Hu; Rishi R Agrawal; Andrew J Murphy; Ira J Goldberg; Richard J Deckelbaum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.